| Literature DB >> 32346076 |
Nobuhisa Yoshikawa1, Kosuke Yoshida2, Satoshi Tamauchi2, Yoshiki Ikeda2, Kimihiro Nishino2, Kaoru Niimi2, Shiro Suzuki2, Fumitaka Kikkawa2, Hiroaki Kajiyama2.
Abstract
The prognostic nutritional index (PNI), which reflects preoperative malnutrition, is useful for predicting the incidence of postoperative complications and has been reported in recent years to predict the long-term prognosis of various malignancies. The purpose of this study was to clarify the significance of PNI as a prognostic factor for early-stage clear cell ovarian carcinoma. A total of 82 patients with stage I-II (FIGO 2014) ovarian clear cell carcinoma undergoing primary surgery at our hospital from January 2005 to December 2017 were enrolled. PNI was calculated using the formula: 10 × serum albumin (g/ dL) + 0.005 × peripheral blood lymphocyte count (/mm3). Preoperative PNI exhibited relatively high area under the curve value (0.709) for 5 year survival, and the optimal cutoff value was 46.5. The overall survival was significantly shorter in the PNI-low group than in the PNI-high group. Multivariate analysis showed that high PNI was a significant independent prognostic factor for favorable prognosis (hazard ratio = 0.102, p = 0.010). There was no significant difference in recurrence-free survival between the two groups (p = 0.220), but the postrecurrence survival was significantly longer in the PNI-high group than in the PNI-low group (p = 0.0383). The preoperative PNI was a useful predictor of prognosis, even in early-stage ovarian clear cell carcinoma.Entities:
Mesh:
Year: 2020 PMID: 32346076 PMCID: PMC7189228 DOI: 10.1038/s41598-020-64171-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Receiver operating characteristic curve analysis of preoperative PNI. AUC, area under curve; PNI, prognostic nutritional index.
Patients’ perioperative clinical characteristics stratified by PNI. PNI, prognostic nutritional index; TWBC, total white blood cell; Hb, hemoglobin; SD, standard deviation; NA, not applicable; BMI, body mass index.
| All case (n = 82) | PNI-low (n = 35) | PNI-high (n = 47) | ||
|---|---|---|---|---|
| 0.631 | ||||
| mean ± SD | 53.45 ± 10.18 | 51.6 ± 10.3 | 54.8 ± 10.0 | |
| 0.148 | ||||
| mean ± SD | 21.23 ± 3.63 | 20.43 ± 2.93 | 21.84 ± 3.99 | |
| 0.05 | ||||
| I | 74 (90.2) | 29 (82.8) | 45 (95.7) | |
| II | 8 (9.8) | 6 (17.1) | 2 (4.3) | |
| 0.164 | ||||
| Complete staging laparotomy | 56 (68.3) | 21 (60.0) | 35 (74.4) | |
| Others | 26 (31.7) | 14 (40.0) | 12 (25.5) | |
| 0.254 | ||||
| Negative, pseudopositive, or NA | 45 (54.9) | 23 (65.7) | 36 (76.6) | |
| Positive | 23 (28.0) | 12 (35.3) | 11 (23.4) | |
| 0.994 | ||||
| mean ± SD | 6.54 ± 1.91 | 6.54 ± 2.16 | 6.54 ± 1.72 | |
| <0.001 | ||||
| mean ± SD | 1.61 ± 0.59 | 1.31 ± 0.40 | 1.83 ± 0.61 | |
| <0.001 | ||||
| mean ± SD | 12.2 ± 1.52 | 11.5 ± 1.59 | 12.7 ± 1.27 | |
| 0.669 | ||||
| mean ± SD | 281 ± 32.9 | 283 ± 33.3 | 280 ± 32.9 | |
| <0.001 | ||||
| mean ± SD | 3.98 ± 0.49 | 3.56 ± 0.43 | 4.27 ± 0.27 | |
| 0.908 | ||||
| mean ± SD | 197 ± 514 | 205 ± 341 | 191 ± 615 | |
| 0.120 | ||||
| Palitaxel + Carboplatin | 65 (79.3) | 29 (82.9) | 36 (76.6) | |
| Docetaxel + Carboplatin | 3 (3.7) | 0 (0) | 3 (6.4) | |
| Irinotecan + Cisplatin | 4 (4.9) | 3 (8.6) | 1 (2.1) | |
| No | 10 (12.2) | 3 (8.6) | 7 (14.9) | |
| 0.380 | ||||
| ≤3 | 35 (42.7) | 13 (37.1) | 22 (46.8) | |
| > 3 | 47 (57.3) | 22 (62.9) | 25 (53.2) | |
| Diabetes | 6 (7.3) | 2 (5.7) | 4 (8.5) | 0.627 |
| Hypertension | 11 (13.4) | 3 (8.6) | 8 (17.0) | 0.257 |
| Dyslipidemia | 10 (12.2) | 3 (8.6) | 7 (14.9) | 0.379 |
Figure 2Kaplan–Meier curves of the OS and RFS in all patients, stratified by PNI. The OS (A) and RFS (B) in all patients and the OS stratified by PNI (C). The p-value was calculated by the log-rank test. OS, overall survival; RFS, recurrence-free survival; PNI, prognostic nutritional index; HR, hazard ratio; CI, confidence interval.
Figure 3Kaplan–Meier curves of the PRS. The PRS stratified by pretreatment PNI. The p-value was calculated by the log-rank test. PRS, postrecurrence survival; PNI, prognostic nutritional index; CI, confidence interval.
Univariate and multivariate analyses of the factors for overall survival. PNI, prognostic nutritional index; BMI, body mass idex; SD, standard deviation; NA, not applicable; BMI, body mass index.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| 0.596 | 0.1541 | |||
| ≤55 | Reference | Reference | ||
| >55 | 0.679 (0.137–2.825) | 0.306 (0.053–1.577) | ||
| 0.232 | 0.249 | |||
| ≤22 | Reference | Reference | ||
| >22 | 0.320 (0.016–1.879) | 0.297 (0.014–2.112) | ||
| 0.239 | 0.091 | |||
| Complete staging laparotomy | Reference | Reference | ||
| Others | 0.326 (0.017–1.884) | 0.205 (0.010–1.247) | ||
| 0.471 | 0.605 | |||
| Negative, pseudopositive, or NA | Reference | Reference | ||
| Positive | 1.716 (0.352–7.001) | 1.509 (0.284–6.979) | ||
| 0.675 | 0.941 | |||
| ≤197 U/mL | Reference | Reference | ||
| >197 U/mL | 1.425 (0.208–6.206) | 1.069 (0.138–5.449) | ||
| 0.124 | 0.076 | |||
| ≤3 | Reference | Reference | ||
| >3 | 4.090 (0.718–76.816) | 5.862 (0.843–117.674) | ||
| 0.029 | 0.010 | |||
| ≤46.5 | Reference | Reference | ||
| >46.5 | 0.193 (0.028–0.848) | 0.102 (0.008–0.602) | ||